PharmaMar (MSE: PHM) has announced today that it has been rated 'Excellent' by the Spanish Technical Committee for the Program to Promote Competitiveness in the Pharmaceutical Industry (PROFARMA).

The Company obtained this rating for the seventeenth consecutive time, following an evaluation of the results obtained by analyzing PharmaMar on the basis of industrial, economic and R&D parameters, within the current framework of the Spanish industry. The main objective of the PROFARMA Plan is to increase the competitiveness of the pharmaceutical industry in Spain by modernizing the sector and promoting activities that provide greater added value.

PharmaMar is part of Group A, which is comprised of companies with a significant research activity and resources that position them as leaders in R&D. PharmaMar has both a pharmaceutical production plant and its own research and development center, ranging from non-clinical to clinical stages, and is developing numerous collaborations with leading academic centers and hospitals around the world.

Carmen Eibe, Director of Project Coordination at PharmaMar, commented: This decision by the Ministry of Economy, Industry and Competitiveness shows that PharmaMar is at the forefront of biopharmaceutical innovation in oncology in Spain, alongside the most important companies in the sector, and is a globally recognized promoter of research into marine-derived drugs, that increase treatment options for patients with serious diseases.

Contact:

Tel: +34 91 846 6000

Fax: 91 846 6001

(C) 2022 Electronic News Publishing, source ENP Newswire